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Abstract
Background: Mesothelin has attracted much interest as a tumor specific antigen; it has been reported to promote
tumor development and to be a good target for cancer treatment. Most studies to date have used human
mesothelin in immunocompromised mice. Since these models do not allow for study of the natural immune
response to mesothelin expressing tumors, we have undertaken the characterization of mouse mesothelin so the
effects of this protein can be assessed in immunocompetent mouse strains.
Methods: We analyzed mouse mesothelin expression, tissue distribution, shedding and biochemistry. In addition
we constructed stable mesothelin overexpressing lines of the pancreatic cancer line Panc02 by two methods and
tested them for growth and tumorigencity in vitro and in vivo.
Results: We show here that mouse mesothelin is similar to human mesothelin in biochemical characteristics, tumor
expression and tissue distribution, suggesting the mouse may be a suitable model for study of mesothelin. Stable
overexpression of mesothelin in a pancreatic cancer cell line did not increase cell proliferation or anchorage-
independent growth in vitro, suggesting that mesothelin is not necessarily a tumor progression factor. Surprisingly
overexpression of mesothelin inhibited tumor formation in vivo in immunocompetent mice.
Conclusion: The mouse may be a good model for studying mesothelin in the context of an intact immune
response. Mesothelin is not necessarily a tumor progression factor, and indeed mesothelin overexpression inhibited
tumor growth in immunocompetent mice.
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Background
Human mesothelin is normally expressed only in meso-
thelial cells of the pleura, peritoneum, and pericardium.
However, mesothelin is overexpressed in a high percent-
age of ovarian, pancreatic, non–small cell lung, and
mesothelioma tumors [1–4], and thus is thought to play
a role in development of certain cancers. The homeo-
static function of mesothelin in mammals is unknown,
and the gene can be deleted without apparent effect in
mice [5]. Human mesothelin has been proposed to be a
malignancy factor as it increased tumor cell proliferation
and migration in vitro and tumor size in nude mice [3]
and increased cell proliferation in lung adenocarcinomas
[6]: mesothelin has also been reported to increase cell in-
vasion [7, 8]. Furthermore, siRNA specific for mesothelin
suppressed tumor growth in a rat renal carcinoma model
[9]. Mesothelin interacts with CA125/MUC16 ovarian
cancer antigen, and this interaction has been hypothesized
to play a role in metastasis of ovarian cancers [10].
Since mesothelin expression is largely limited to can-
cerous cells in the adult, it may also be an effective tar-
get tumor antigen for anti-cancer vaccines or therapies
[3, 11–14]. Strategies targeting mesothelin have shown
some efficacy in phase 1 clinical trials [15]. Both anti-
bodies and T lymphocytes have been shown to have pro-
tective anti-mesothelin activity [3, 13, 16, 17]. This fact
may be especially useful because irradiation of tumor
cells enhances the expression of mesothelin [14], so that
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the combination of these treatment modalities may be
synergistic.
Human mesothelin has been well characterized, and
the role of human mesothelin in tumor growth and
treatments in immunocompromised mice has been ex-
plored [3, 6, 7, 9]. However, these models preclude study
of interactions of the tumor with an intact host immune
system that may be crucial for its control. Thus, we
wanted to characterize mouse mesothelin, to determine
its expression, transforming activity, and to develop
models in immunocompetent mice to study the role of
this important protein. We describe here the expression
of mesothelin in murine tissues and cancer cells and
show that its overexpression has little effect on cell pro-
liferation or anchorage independence, yet mesothelin
overexpression impedes tumor growth in the murine
pancreatic adenocarcinoma Panc02 model [18]. Pancre-
atic cancer is the 5th leading cause of cancer deaths in
the United States [19], largely owing to the fact that ra-
diation, surgery, and chemotherapy are ineffective. New
treatment strategies are essential, and our data under-
score that mesothelin studies should be carried out in
vivo in immunocompetent mammals.
Methods
Cell lines and antibodies
The C57BL/6 chemically-induced pancreatic adenocarcin-
oma cell line, Panc02, was a kind gift from Dr. Keping Xie
(MD Anderson Cancer Center, Houston, TX). NIH3T3,
mouse embryonic fibroblast cell line (CRL-1658), Lewis
Lung, and EL4, mouse T lymphoblast thymoma (TIB-39),
were kind gifts of Dr. Kathryn Verbanac (East Carolina
University, Greenville, NC). OVCAR3 (ATCC HTB-161),
human ovarian adenocarcinoma, was the gift of Dr. Anne
Kellogg (East Carolina University). TRAMP-C3 murine
prostate adenocarcinoma was a gift of Dr. Fred Bertrand
(East Carolina University). J774 mouse macrophage (TIB-
67), MIA PaCa-2 (CRL-1420), and HPAC (CRL-2119) hu-
man pancreatic carcinomas were obtained from ATCC.
HEKGP2-293 (Clontech) was derived from HEK cells.
Murine mesothelioma AB12 cell line was the kind gift of
Dr. Wayne Aldrich, Cleveland Clinic [20]. The JWF2 mur-
ine keratinocyte carcinoma cell line was a kind gift from
Dr. Rukiyah VanDross, East Carolina University). The rat
IgG2a anti-mouse mesothelin monoclonal antibody (clone
B35 [10]) was obtained from MBL (Woburn, MA) and the
rabbit anti-β-actin antibody was obtained from Cell Signal-
ing Technology. Secondary antibodies for flow cytometry
(Cy5 conjugated) and Westerns (HRP-conjugated) were
obtained from Jackson Immunoresearch (West Grove, PA).
RT-PCR to detect mesothelin
Total RNA was isolated from wild type (WT) Panc02
using trizol, and cDNA was synthesized using iScript kit
(Biorad, Hercules, CA). Endpoint PCR was performed
using the iScript cDNA and puReTaq Ready-To-Go PCR
beads (GE Healthcare, Piscataway, NJ) in a Geneamp PCR
System 9700. The PCR primers were designed using Inte-
grated DNA Technologies web site. Primers for murine
mesothelin were: ACCGACGAGGAACTGAATGCTCTT,
and ACGATGGACTCATCCAACACTGCT. Primers to
detect GAPDH expression were: AACTTTGGCATTGTG
GAAGGGCTC and ACCCTGTTGCTGTAGCCGTATT
CA. GAPDH control yielded a product size of 449 and the
mesothelin amplicon was 473 bp. The PCR products were
run on a 1 % agarose gel and the bands visualized with a
Bio Doc-IT camera system (Fig. 2a).
Flow cytometry
Panc02 cells were washed with DPBS and cells har-
vested by Trypsin-free Cell Dissociation Solution (Sigma-
Aldrich). Cells were incubated in cold flow buffer (DPBS
with 0.2 g % BSA + 0.01 % sodium azide) with 1:1000 of
MBL B35 rat monoclonal antibody or normal rat IgG for
background control. Following 30 minute incubation on
ice, donkey anti-rat Cy5 conjugated secondary antibody
was added at 1:100. Cells were incubated for an additional
30 minutes on ice, washes repeated and cells were fixed
with 1 % electron microscopy grade paraformaldehyde
(Electron Microscopy Sciences, Hatfield, PA) diluted in
DPBS. Data were acquired on a BD LSR II (BD Biosci-
ences) and data analysis was conducted using BD FACS-
Diva or FlowJo software. We found that trypsin cleaves
mesothelin from the surface, so in experiments with ad-
herent cells, cells were dissociated from the surface using
trypsin-free solutions.
Stable overexpression of mesothelin in Panc02 cells by
transfection
Full length mouse cDNA mesothelin sequence was cut
from pCMV-SPORT6-meso (OpenBiosystems) by EcoRI
and NotI and cloned into EcoRI and NotI sites of pcDNA
3.1 (+) expression vector (Invitrogen). The mesothelin
cDNA was sequenced in the pcDNA3.1-meso vector to
confirm the correct sequence. Panc02 cells were trans-
fected with pcDNA 3.1 –meso using Lipofectamine 2000
(Invitrogen) following the manufacturer’s instructions.
After 48 h transfection pcDNA-meso positive cells were
selected with G418 for 10 days (at this time, all the control
Panc02 were dead). Clones of Panc02-meso were obtained
by limiting dilution. Control Panc02-pcDNA vector cells
were obtained by Panc02 cells transfected with pcDNA
3.1 null vector and selected with G418.
Stable overexpression of mesothelin in Panc02 cells by
retroviral (RV) gene transfer
SalI and XbaI were used to cut full length mouse meso
cDNA sequence from pCMV-SPORT6-meso, which was
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cloned into the SalI and AvrII sites of the pLXRN Retro-
viral Expression Vector (Clontech, Mountain View, CA).
Subsequent sequencing of cloned pLXRN-meso con-
firmed the correct mesothelin cDNA sequence. GP2-293,
pantropic virus packaging cell line (Clontech), was co-
transfected per manufacturer’s instructions with pLXRN-
meso (or pLXRN null vector) and pVSV-G (Clontech),
using Lipofectamine 2000 (Invitrogen). Virus-containing
supernatants from both cultures of GP2-293 were har-
vested at 72 h, 0.45 μ filtered, polybrene 1 ug/ml added
and used to infect WT Panc02 cells. G418 was added at
48 h post infection to select stably overexpressing or vec-
tor control cells, and overexpressing cells were cloned by
limiting dilution.
Rabbit anti mouse mesothelin anti-peptide antibody
Peptides representing murine mesothelin coding se-
quence, GVYGFQVSEADVRALGGLAC and CPPGKEPY
KVDEDLIFYQN, were synthesized and conjugated to
KLH carrier proteins via the terminal cysteine residues
(bold, Genemed Synthesis), and used for immunization of
two rabbits. Sera were confirmed for reactivity with the
immunizing peptides by ELISA. Antibodies were also
purified from this sera using peptide CPPGKEPYKV
DEDLIFYQN which is in the carboxy portion of the pro-
tein, after the furin cleavage site (see Fig. 1).
Western immunoblot
Panc02, NIH/3 T3, and GP2 HEK-293 cells were lysed
in lysing buffer (Tris–HCl 50 mM pH 7.4, sodium deox-
ycholate 0.25 %, IGEPAL CA-630 1 %, NaCl 150 mM,
EDTA 1 mM, EGTA 1 mM) containing 1× HALT Prote-
ase Inhibitor cocktail (Pierce Chemical, Rockford, IL)
and centrifugation at 14,000 × g for 15 minutes. Super-
natant was collected and a BCA Assay (Pierce Chemical)
performed to quantify total protein. Tissues from C57Bl/
Fig. 1 Alignment and high similarity of mouse (top line) and human mesothelin protein sequences. Mouse mesothelin (625 amino acids) is
predicted to have an amino terminal signal peptide, a furin cleavage site at position 298, and a carboxy-terminal glycosyl-phosphatidylinositol
(GPI) linked anchor sequence. Signal peptide, N-linked glycosylation consensus sites, furin cleavage sequence, and GPI-anchor are underlined, and
peptides used as the immunizing antigen for anti peptide antibody production are shaded
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6 mice were harvested and homogenized in lysis buffer
with 1× HALT at 100 mg tissue/ml buffer using a Poly-
tron PT 1200E. Homogenized samples were centrifuged,
supernatants harvested and protein levels determined by
BCA assay as above. Total proteins (40 μg/lane in sam-
ple buffer containing 0.1 M dithiothreitol) were sub-
jected to electrophoresis on 8 % SDS-acrylamide gels.
Proteins were transferred to PVDF membranes in
Towbin’s transfer buffer for 75 min at 175 mA (XCell II
Blot Module, Invitrogen) and blocked in 5 % powdered
milk in TBST. Blots were incubated with a 1:8000 dilution
of rabbit anti-mouse mesothelin polyclonal antisera in 5 %
milk/TBST overnight at 4 °C. Blots were incubated with
donkey anti-rabbit IgG peroxidase-conjugated antibody
(1:8,000) and proteins visualized by luminol-enhanced
chemiluminescence using Lumiglo ECL reagent (NEB)
and exposure of membranes to x-ray film (Hyperfilm
ECL, GE Healthcare Amersham). For detection of
mesothelin overexpression with pcDNA or RV in the 6
clones, 4, 1.8 × 106 Panc02 cells were lysed with 200 ul 1×
disruption buffer (4 % SDS, 4 % ß-mercaptoethanol,
0.05 M Tris base, 10 % Glycerol 0.1 % Bromphenol blue).
The cell lysate was passed through 22 Gauge needle and
26 ul lysate was heated at 100 °C for 10 min and loaded
on an 8 % SDS gel and processed for western blot as de-
scribed above. For measurement of actin, the blot was
stripped with BlotFresh Western Blot Stripping
Reagent (SignaGen Lab) and incubated with 1:1500
dilution of rabbit anti actin antibody (Cell signaling,)
followed by donkey anti-rabbit IgG peroxidase-
conjugated antibody (1:8000) and development by chemi-
luminescence. For Western analysis on supernatants, cells
were cultured in RPMI 1640 medium supplemented with
1 % of FBS, 1 mM of sodium pyruvate, 100 uM of NEAA
0.05 mM of ß-mercaptoethanol and 300 ug/ml of Genet-
icin (GIBCO). One day later, the supernatants were har-
vested and 16:1 concentrated using Millipore 10 kDa
Centrifugal Filter Units. BCA assay was used to measure
the protein concentration of the concentrated super-
natant. 50 ug of the supernatant protein was mixed with
sample loading buffer with 0.1 M dithiothreitol, heated at
100 °C for 10 minutes, loaded on a 10 % SDS gel and
processed for Western blot as above.
Tumor model
Female C57BL/6 mice (Charles River, 10 and 14 weeks
of age) were used for experiments. All mice were housed
in the East Carolina University Department of Compara-
tive Medicine AAALAC accredited animal facility and
kept in conventional conditions with full access to food
and water throughout the study. All procedures were ap-
proved by the Institutional Animal Care and Use Com-
mittee and in accordance with recommendations for
proper care and use of laboratory animals. Groups of
mice (n = 4–8 per group) were injected s.c. in the right
flank with Panc02 cells (6.4x105), one injection per
mouse, under isoflurane (3 %) inhalation anesthesia. Tu-
mors were allowed to grow until palpable, and tumor
size was measured three times per week by a digital cali-
per, and volume was calculated as [(smallest diameter2) x
largest diameter]/2. Mice were humanely euthanized to
minimize pain or distress if they reach endpoints of tumor
size, ulceration, or impairment.
Panc02 in vitro growth MTS assay
Panc02 cells were seeded in 96-well plates (15,000 cells/
100ul/well), at serum concentrations from 0-10 %, and
after 24 h, 10 μl of MTS/PMS (2.0 mg/ml MTS, Pro-
mega and 0.1 mg/ml PMS, Sigma) was added. The ab-
sorbance was read at 492 nm. Media only was used to
define the background control level. In another experi-
ment, 100 cells/well were seeded into wells of a 6 well
plate and allowed to grow for 10 days. MTS/PMS was
added and readings were performed as above.
Soft agar assay
A base layer of 1 m1 of 0.5 % agar in RPMI was poured
into wells in a 6 well plate and cooled to solidify. 2 ml of
warmed (40 °C) 0.2 % agarose/RPMI cell solution (25,000
cells per ml) were layered on top of each well. Cells were
incubated at 37 °C 5 % CO2 for 3 weeks. 500 ul of RPMI
per well were added once per week. Wells were photo-
graphed macro-and microscopically for colony counting
and measurement.
Statistical analysis
Statistical analysis consisted of ANOVA using the 5
groups (wild type, vector, and 3 clones) for both the
pcDNA and the RV vectored mesothelin overexpressing
clones with post hoc testing with a Tukey adjustment.
Students t test was used to assess significance between
vector and mesothelin overexpressing lines.
Tumor section staining
Frozen tissue was embedded in Frozen Section Medium
(Azer Scientific), cut on a cryostat (5 um), and mounted
onto Superfrost Plus glass microscope slides. Tissue was
fixed on slides with acetone (−20 °C) and endogenous
peroxidase activity was blocked with 0.6 % hydrogen
peroxide. Slides were placed on Shandon coverplates™
(Thermo Fisher) using 0.2 % Triton-× 100/PBS and
placed in a Sequenza™ slide rack (Thermo Fisher). Slides
were incubated with Biotin conjugated rat anti-mouse
CD8 (eBioscience, 1:50 in 1%BSA/PBS), or diluent as
negative control, and then with Vectastain Elite ABC
(Vector Laboratories, Burlingame, CA), developed with
Vector DAB Peroxidase substrate (Vector Laboratories)
and mounted with Permount (Thermo Fisher).
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Results
Mouse mesothelin
Figure 1 shows the alignment and high similarity of
mouse (top line) and human mesothelin protein se-
quences. Mesothelin is highly conserved, and BLAST-p
shows that mouse mesothelin shares 92 % identical or
conservative substitutions to rat mesothelin, 71 % to hu-
man mesothelin, 70 % to rhesus monkeys, and 74 % to
dog. Mouse mesothelin is predicted to have an amino
terminal signal peptide, a furin cleavage site at position
298, and a carboxy-terminal glycosyl-phosphatidylinositol
(GPI) linked anchor sequence also conserved in the rat
and human orthologs [21]. Similar to human and rat se-
quences, the murine mesothelin sequence is predicted to
be 625 amino acids, which would result in a mature pro-
tein of approximately ~65 kDa (if the putative signal se-
quence is cleaved). Furin cleavage of mouse mesothelin
would be predicted to result in a released amino terminal
fragment of ~29 kDa and a membrane-bound carboxy ter-
minal fragment of ~37 kDa. However, since each of these
2 major fragments has N-linked glycosylation sites (1 in
the soluble amino terminal fragment and 3 in the mem-
brane bound form) in human and mouse, the glycosyla-
tion patterns determine the actual molecular weight of the
proteins expressed in cells. Interestingly, in the human,
the carboxy terminal portion of mesothelin (from the
furin cleavage site to the gpi linkage) is also reported to be
released from the cell surface [22, 23].
Mesothelin surface expression
Since there was a dearth of characterized murine
mesothelin reagents available, we first assessed murine
mesothelin expression using sequence information and
RT-PCR. Mesothelin is reported to be over-expressed in
pancreatic cancer cells, so we assessed mesothelin ex-
pression in the Panc02 murine pancreatic adenocarcin-
oma line. We were able to detect mesothelin RNA
expression in these cells by RT-PCR (Fig. 2a).
Protein sequence analysis suggested that murine
mesothelin would be expressed on the surface of cells
similar to human mesothelin. In order to detect surface
protein expression of mesothelin, we assessed the B35
monoclonal antibody made to LO cells (murine embry-
onic endothelial-like cells) that was suggested from func-
tional studies to bind murine mesothelin [10]. This
antibody recognized a protein on the surface of Panc02
cells, and the protein was removed from the surface by
trypsin (Fig. 2b). Therefore, subsequent flow cytometry
experiments were performed with cells that were
scraped or dislodged by metal ion chelation to avoid the
Trypsin Scraped Panc02
Panc02M     G    
GAPDH: 473 bp
Mesothelin: 449 bp
a RT-PCR Panc02 b
Mesothelin – Cy5
HEK293              HEK293+Meso AB12               TRAMP-C3                JWF2
NIH/3T3 J774            Lewis Lung    OVCAR3 (human)   HPAC (human)
# 
C
el
l
# 
C
el
l
c
Fig. 2 Expression of murine mesothelin. a RT-PCR detection of mesothelin (M, 449 base pairs) and control GAPDH (G, 473 bp) RNA in Panc02 cells.
b Mesothelin protein surface expression – cells were stained with rat anti-mouse mesothelin monoclonal antibody B35 (black line) or normal rat IgG
(gray line) and Cy5-conjugated donkey anti-rat IgG and analyzed by flow cytometry. Top right panels show that Panc02 surface detection is reduced
by trypsin treatment compared to scraping of the adherent cells into solution. Adherent Panc02 cells were harvested by treatment with Trypsin/EDTA
cocktail or by scraping. c Because trypsin reduced mesothelin detection, all subsequent experiments on adherent cells were performed using
chelating agents without trypsin. Mesothelin expression was detectable on mouse-mesothelin-transfected HEK, and several mouse cancer cell lines:
AB12 mesothelioma, TRAMP-C3 prostate adenocarcinoma, the JWF2 keratinocyte squamous cell carcinoma, and NIH/3 T3 cells
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use of trypsin. To determine the specificity of the B35
antibody for mouse mesothelin, we performed a trans-
fection experiment. Transfection of HEK293 cells with
murine mesothelin resulted in >100 fold increase mean
fluorescence intensity compared to vector transfected
cells. These data constitute the first direct evidence that
the B35 antibody detects mesothelin (Fig. 2c).
We next wanted to characterize the expression of
mesothelin in various mouse cell types. As shown in
Fig. 2c, mesothelin expression was detectable on several
mouse cancer cell lines: AB12 mesothelioma, TRAMP-
C3 prostate adenocarcinoma, and the JWF2 keratinocyte
squamous cell carcinoma. It was also detected on MEF
and NIH/3 T3 embryonic fibroblast lines, consistent
with previous detection during embryogenesis [5]. How-
ever we found for the mouse, as in humans, mesothelin
protein expression was largely confined to certain can-
cers. A number of murine cell lines did not express
mesothelin, including: P815 mastocytoma, YAC-1 and
EL4 T lymphomas, B16-F10 melanoma (not shown),
Lewis lung carcinoma, the J774 macrophage/monocyte
cell line (Fig. 2c). In addition the B35 antibody did not
detect mesothelin on any human cells tested; HEK-293,
OVCAR3, and HPAC (Fig. 2c) and MIA PaCa2 (not
shown). Since OVCAR3 and HPAC cells are reported to
be positive for human mesothelin, these data suggest
that the B35 antibody is specific for murine mesothelin.
Thus, our data show that the distribution of murine
mesothelin is limited to certain cancers similar to hu-
man mesothelin expression and suggest the use of cer-
tain mouse tumor models for the study of mesothelin.
Mesothelin expression in mouse tissues
It was reported that murine mesothelin gene expression
was detected in certain embryonic stages as well as in
several adult tissues, but protein expression was not
tested previously [5]. While the B35 anti-mesothelin
antibody did not work in a denaturing western blot, we
were able to detect mouse mesothelin by preparing an
affinity purified polyclonal rabbit antibody. Mesothelin
was detected as a ~49 kDa protein in some mouse tis-
sues and in HEK 293 cells transfected with a mesothelin
expressing plasmid (Fig. 3a). The apparent molecular
weight of the mesothelin protein is consistent with the
predicted molecular weight of the furin-cleaved mature
glycosylated protein (37 kDa plus glycosylation). A full-
length precursor mesothelin protein at the predicted
66 kDa (plus glycosylation) was not clearly visible on
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Fig. 3 Mesothelin expression in normal mouse tissues and cell lines. a Cell lines and naive C57Bl/6 mouse tissues (including peritoneal membrane,
pancreas and diaphragm) were harvested, prepared and assayed as described in Methods. Samples were subjected to denaturing electrophoresis on
8 % SDS-acrylamide gels. Immunoblots were probed with polyclonal affinity-purified rabbit anti-mouse mesothelin antibody and HRP-conjugated
donkey anti-rabbit antibody. Arrows point to mesothelin protein bands b Mesothelin can be detected by unpurified rabbit anti mesothelin antisera in
supernatants of Wt Panc02 cells, with increased levels in Panc02 cells containing retrovirus constructs (RV) over-expressing mesothelin (RV clone 4, RV
clone10), compared to Panc02 containing empty vector (RV vector). Mesothelin can also be seen in HEK 293 cells transfected with a mesothelin
expressing plasmid (293 Meso). c Mesothelin can be detected in supernatants (RVclone 4) using sera purified on peptide PPGKEPYKVDEDLIFYQN in the
carboxy terminal half of the mesothelin protein. The purified antibody detects the 49 kDa form of mesothelin, but not the 34 kDa form
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gels suggesting that the furin cleavage is rapid. Consist-
ent with the flow cytometry data (Fig. 2), we detected
mesothelin in Panc02 and NIH 3 T3 cells (Fig. 3a).
Mesothelin protein was also detected in Panc02 tumor
excised from a mouse, and in normal mouse peritoneal
membrane and ovary, as previously described in human
tissue [24]. Relative protein expression levels in the dif-
ferent tissues may be inferred from comparison to back-
ground staining bands on the blot. HEK 293 cells, and
normal mouse diaphragm, spleen, lung, pancreas and
liver did not express substantial levels of mesothelin,
underscoring the restricted expression of this protein in
mice. These data indicate that murine mesothelin ex-
pression is similar to human in that it is not broadly
expressed on many tissue types, suggesting that mesothe-
lin may be an appropriate tumor-specific target for
treatment.
Mesothelin release
Mesothelin has been reported to be released from cells
expressing it [22, 23], so we measured mesothelin in su-
pernatants of cultured Panc02 cells. Figure 3b shows
that wild type (wt) Panc02 cells and HEK 293 cells trans-
fected with a pcDNA plasmid expressing mesothelin
have a protein supernatant band at ~49 kDa (similar to
mesothelin found in lysates) as well as a ~34 kDa form
that reacts with the rabbit anti mesothelin antisera we
prepared. We constructed Panc02 cells that over-express
mesothelin using a retroviral (RV) construct, and both
the 34-and 49 kDa proteins were greatly increased in su-
pernatants from these cells (RV clone 4 and 10, Fig. 3b).
As the identity of the secreted mesothelin fragments
has been controversial, we also purified rabbit antisera
on peptide CPPGKEPYKVDEDLIFYQN to purify anti-
bodies reactive with the carboxy portion of the furin-
cleaved protein (from the furin cleavage site to the GPI
anchor region). This purified antibody recognized the
49 kDa supernatant protein but not the 34 kDa protein
(even after extended exposure, Fig. 3c). These data sug-
gest that 2 forms of the mesothelin protein are found in
supernatants of murine mesothelin expressing cells, a
49 kDa form that contains sequence from the furin
cleavage site to the GPI anchor region, and a 34 kDa
form that does not contain the PPGKEPYKVDEDLI
FYQN (Fig. 1), presumably the amino terminal secreted
form.
Mesothelin overexpression
In order to study the biology of mesothelin, we con-
structed stable mesothelin over-expressing Panc02 cell
clones by transfection with pcDNA under the CMV pro-
moter followed by drug selection. Figure 4a shows that
we were able to over-express mesothelin in 3 clones (2,
14, and 17) compared to wild type (wt) Panc02 and
control pcDNA empty vector transfected cells. Panc02
cells show a family of bands around 49 kDa, which are
likely glycoyslation variants of mesothelin. The mature
protein was visible at similar apparent molecular weight
in both Panc02 cells and transfected HEK 293 cells. In
order to study mesothelin over-expression in a vector-and
promoter-independent manner, we also stably overex-
pressed mesothelin in Panc02 by retroviral (RV) transduc-
tion under the LTR promoter. Figure 4b shows that three
clones overexpressed mesothelin compared to wt Panc02
and control empty vector treated cells. There is a similar
grouping of bands visible around 49 kDa as well as some
smaller bands that react with this antibody.
Mesothelin overexpression on the surface of cells
In order to determine whether over-expressed mesothe-
lin is displayed on the surface of cells, we performed
flow cytometry. Figure 5 shows that all 6 clones that
over-expressed mesothelin by western blot also over-
expressed mesothelin on the cell surface compared to wt
Panc02 and empty vector control cells. Mean fluores-
cence intensities increased 2–3 fold in the mesothelin
over-expressing cells. Thus, these data confirm the re-
sults in Fig. 4 and indicate that mesothelin was also
expresed on the cell surface where it might more easily
stimulate or interact with an immune response.
In vivo tumor kinetics
Since human mesothelin has been reported to be an ag-
gression/malignancy factor, we wanted to determine the
effect of murine mesothelin overexpression in Panc02
cells. Three stably transfected mesothelin over-expressing
clones (CMV promoter) were compared to vector and
wild type Panc02 injected s.c. for tumor growth kinetics.
Results showed that all mesothelin-overexpressing clones
grew tumors significantly more slowly in immunocompe-
tent syngeneic mice than either wild type Panc02 or
pcDNA empty vector control (Fig. 6, top). To determine
whether mesothelin overexpression reduced tumor
growth or if this might be due to the particular promoter
or plasmid construct, we also assessed mesothelin ing
Panc02 clones constructed using the retroviral (RV) trans-
duction system with mesothelin under the LTR promoter.
Results were similar: all three RV mesothelin over-
expressing clones tested developed tumors more slowly in
mice than either wild type or vector control (Fig. 6). Stu-
dent’s t-test showed statistical significance p < 0.01 for all
6 overexpressing clones (compared to corresponding vec-
tor) after day 24. ANOVA showed significant differences
(p <0.05) between 1) the wild type and vector groups, and
2) the 3 RV mesothelin overexpressing clones on Days
30–39 (except for day 35): and for the pcDNA clones be-
tween 1) the wild type and vector groups, and 2) the 3
pcDNA mesothelin-overexpressing clones on days 30–41.
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Exp #1:  wt Panc02 RV-Vector            RV Clone 2             RV Clone 4 RV Clone 10
Exp #2:  wt Panc02      pcDNA Vector   pcDNA  Clone2    pcDNA Clone14  pcDNA Clone17
MFI:364 MFI:240 MFI:997 MFI:1009 MFI:1068
MFI:290 MFI:570MFI:214 MFI:728 MFI:415
Fig. 5 Mesothelin expression on the cell surface. Panc02 wild type (wt), retrovirus (RV), clones 2, 4, 10; or pcDNA clones 2, 14, and 17, or control
null vector cells were incubated with monoclonal antibody B35 (black line) or normal rat IgG (gray line) and Cy5-conjugated donkey anti-rat IgG
and analyzed by flow cytometry. Mean fluorescence intensities (MFI) show increased mesothelin in overexpressing clones. RV clones expressed
significantly more mesothelin than vector and wild type p < 0.001. pcDNA clones 2 and 14 expressed significantly more mesothelin than vector
and wild type p < 0.05
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Fig. 4 Overexpression of mesothelin. a pcDNA- Clones of Panc02 cells (clones 2, 14 and 17) stably transfected with pcDNA mesothelin under the
CMV promoter show higher levels of mesothelin expression than wild type Panc02 cells and empty pcDNA vector Panc02 cells. HEK293 cells transiently
transfected with empty vector or mesothelin expressing pcDNA vector (293Meso) are shown as control. b Overexpression of mesothelin is seen in
stably transduced retrovirus (RV) clones of Panc02 (clones, 2, 4, and 10), compared to retrovirus vector. HEK 293 cells transiently transfected with
mesothelin over-expressing plasmid or empty vector are shown as controls
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It should be noted that both the vector groups and the
overexpressing clones express the neomycin resistance
gene and were selected on G418, so differences are not at-
tributable to neomycin expression. These results sug-
gested that increasing mesothelin expression in Panc02
cells did not accelerate tumor growth as expected [3], and
in fact inhibited it
Panc02 growth kinetics in vitro
To determine whether the slower growth rate of the
mesothelin over-expressing clones seen in vivo was due
to the inherent growth rate of the clones or another
mechanism of control of tumor growth in vivo, we
tested the proliferation of wtPanc02, empty vector trans-
fected, or mesothelin over-expressing Panc02 clones in
vitro. The empty vector control cells contain the neomy-
cin resistance gene and were selected on G418 similar to
the selection of the clones. As shown in Fig. 7, the
growth rate (slope) of all Panc02 cells was similar, with
the wild type Panc02 cells in the middle of the group
of cells with some mesothelin over-expressing clones
showing higher and some showing lower proliferation
(the results depend on the exact number of cells counted
and plated at the beginning of the experiment). There
was no clear trend, suggesting that the level of mesothelin
expression did not itself affect the rate of proliferation.
This suggests the mesothelin overexpression did not have
toxic effects in the cells. In five experiments with various
cell and serum concentrations, out to 10 days of growth,
no consistent significant mesothelin-dependent growth
effect was detected. These results indicated that the
Panc02 cells and the mesothelin overexpressing clones
grew at a similar rates in vitro and suggest that the
growth rate of the mesothelin overexpressing clones
(Fig. 6) was slowed significantly by some in vivo effector
in the mouse tumor model where there is an intact im-
mune system.
Anchorage independent growth
It has also been previously reported that mesothelin pro-
moted anchorage independent colony formation in vitro
[3], considered an in vitro measure of transformation.
We analyzed Panc02 wild type, null control vector, and
mesothelin over-expressing clones for colony formation
in soft agar. We found that the six mesothelin over-
expressing clones (3 retrovirus and 3 pcDNA constructs)
did not reproducibly form higher numbers of colonies or
larger colonies than vector controls (Fig. 8). While there
was variability in individual experiments with some
clones higher or lower than vector control, the mesothe-
lin overexpressing clones usually formed fewer colonies
compared to vector controls when counted microscopically,
but there were no statistically significant differences. To-
gether these data indicate that mesothelin overexpression
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overexpressing stable Panc02 cells constructed using retrovirus (RV,
clones 2, 4, 10) or pcDNA transfection (clones 2, 14, and 17) or
control null-vector containing Panc02 cells. Tumor volumes were
measured 3 times per week. Standard error bars are shown and Stu-
dent's t-test showed statistical significance *p < 0.01 for all 6
overexpressing clones after day 24. ANOVA showed significant
differences (p <0.05) between 1) the wild type and vector groups
and 2) the 3 RV mesothelin overexpressing clones on days 30–39
(except for day 35): and for the pcDNA clones between 1) the wild type
and vector groups, and 2) the 3 pcDNA mesothelin-overexpressing
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Fig. 7 Mesothelin effect on in vitro growth. Wild type (WT) Panc02,
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retrovirus (RV, clones 2, 4, 10) or pcDNA transfection (clones 2, 14,
and 17) or control null vector containing Panc02 cells were seeded
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does not promote cell proliferation or anchorage inde-
pendent growth of Panc02 cells.
Tumor histology and metastases
In order to view the effects of mesothelin overexpression
in vivo, we performed hematoxylin and eosin staining of
tissue sections from both pcDNA and retroviral vector
mesothelin-overexpressing tumors and control vector
tumors (Fig. 9). Epithelial type tumor cells were dominant
in all tumors, with viable tumor cells and vasculature
throughout and little visible necrosis. Little evidence
of leukocytic infiltration was seen in mesothelin-
overexpressing or vector control tumors. The mesothelin
over-expressing tumors showed an apparent increase in
epithelial to mesenchymal transition. The vector control
tumors displayed the typical epithelial cobblestone appear-
ance, while over-expression of mesothelin caused more
spindle-shaped mesenchymal type cell morphology. The
RV- Vector RV clone 2 RV clone 4 RV clone 10
pcDNAvector pcDNA 2 pcDNA 14 pcDNA 17
Fig. 8 Soft agar assay. A base layer of 1 ml of 0.5 % agar in RPMI was poured into wells in a 6 well plate and cooled to solidify. 2 ml of warm
(40 °C) 0.2 % agarose/RPMI cell solution (25,000 cells per ml) were layered on top of each well. Cells (vector control or corresponding mesothelin-
overexpressing clones) were incubated at 37 °C 5 % CO2 for 3 weeks. 500 ul of RPMI per well were added once per week. Wells were photographed
macro-and microscopically for colony counting and measurement
pcDNA vector control     pcDNA mesothelin
RV vector control     RV mesothelin
Fig. 9 Tumor cell morphology. Control vector (pcDNA plasmid and retroviral vector [RV]) and mesothelin overexpressing tumors harvested from
mice (Fig. 6) were frozen, fixed, and stained with hematoxylin and eosin. Vector control tumors (left) show epithelial cobblestone morphology
while mesothelin over-expressing tumor cells (right) show more spindle shaped morphology
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tumor cells overexpressing mesothelin also appeared to
have increased production of extracellular matrix (Fig. 9).
To determine whether there was increased specific im-
mune response to mesothelin, we performed immuno-
histochemical staining for CD8, a marker for cytotoxic T
lymphocytes. As in the hematoxylin staining, little
lymphocytic infiltration was seen in the tumors, and
there was little CD8 antibody signal compared to control
sections with no primary antibody. Spleen cells were
stained as positive controls and showed strong CD8 de-
tection. There was no observable difference in CD8 sig-
nal between control vector tumors and mesothelin
overexpressing tumors (Fig. 10).
Since the epithelial to mesenchymal transition is asso-
ciated with increased metastasis, we macroscopically an-
alyzed lung metastases in mice with control vector
tumors and mesothelin over-expressing tumors. In the
vector control tumor-implanted mice, 5 of 12 mice had
lung metastases (42 %), while in mesothelin over-
expressing tumor-implanted mice, only 2 mice of 26 had
metastases (8 %). Additionally, the numbers of meta-
static foci per mouse were reduced in mice with
mesothelin over-expressing tumors (4 metastases in 2 of
26 mice) compared to control tumors (25 metastases in
5 of 12 mice).
Discussion
The mouse mesothelin sequence is very similar to hu-
man and rat, conserving all the main predicted struc-
tural features of the protein, suggesting that its functions
and biochemistry are similar [21]. The murine mesothe-
lin sequence is predicted to be 625 amino acids, with a
precursor protein of ~65 kDa (plus glycosylation), and
furin cleaved fragments of ~29 kDa (predicted to be se-
creted) and ~37 kDa membrane-bound, which may be
shed from the surface. Our results show that murine
mesothelin can be detected as a ~49 kDa protein on
SDS-PAGE immunoblot, with a 34 kDa band also appar-
ent in some samples. This is consistent with the pre-
dicted molecular weights of the furin-cleaved 29 and
37 kDa fragments, since each of these fragments is pre-
dicted to be glycosylated. We have shown that mouse
mesothelin also has similar expression to human mesothe-
lin, that it is restricted to certain organs and cancer and
embryonic cells, and that murine mesothelin is expressed
on the cell surface as well as released into supernatants,
similar to human cells. The similarities in biochemistry
and expression suggest that mouse mesothelin will make
an appropriate model for studying mesothelin biology and
immunology.
Both carboxy and amino terminal fragments of mesothe-
lin have been reported to be released from cells and are
detectable in supernatants and sera of tumor bearing mice
or humans [21–23, 25], it seems likely that the 49 kDa
form represents the carboxy terminal fragment and the
34 kDa fragment is the amino terminal portion of the
mesothelin, however it is possible that the 34 kDa form is
a degradation product missing the amino acid sequence
used to elicit the antisera (Fig. 1). The smaller amino ter-
minal fragment is predicted to be secreted because of its
signal sequence. The carboxy terminal fragment is pre-
dicted to be membrane bound by gpi anchor, however gpi
proteins can be shed from the cell surface by cleavage by
several proteases. The biological effects of the shed
mesothelin are unknown, but these fragments may be use-
ful for diagnostic purposes, or they might interfere with
mesothelin-specific immune responses.
Human and mouse mesothelin expression have been
implicated in the development of cancer [3, 26, 27]. To
understand the role that mesothelin plays in cell trans-
formation, we constructed stable mesothelin over-
expressing Panc02 clones using both retroviral and
pcDNA stable transfection methods. We determined that
mesothelin overexpression (in 6 clones) did not increase
pcDNA vector control, CD8    pcDNA mesothelin, CD8 spleen, no primary
RV vector control, CD8   RV mesothelin, CD8    spleen, CD8
Fig. 10 Control vector (pcDNA plasmid and retroviral vector [RV]) and mesothelin overexpressing tumors harvested from mice (Fig. 6) were
frozen, fixed, and stained with biotin conjugated rat anti-mouse CD8, Vectastain Elite ABC and developed with Vector DAB Peroxidase substrate.
Spleen cells (positive control) show strong staining of CD8+ cells compared to negative control (no primary antibody) or tumor tissue sections
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cell proliferation in vitro or transformation as measured
by the soft agar colony formation assay (Figs. 7, 8). In
addition, mesothelin overexpression reliably caused a de-
crease in a heterotopic tumor growth in an immunocom-
petent syngeneic mouse model, when compared to wild
type or stable vector transfected/transduced Panc02 lines.
Other cell lines should be tested for effects of mesothelin
expression levels since perhaps Panc02 cells already ex-
press a high/saturating level of mesothelin, but our data
show that the NIH 3 T3 cells express higher mesothelin
levels (Fig. 3). Our data are in contrast to data reported on
human mesothelin in the MIA PaCa-2, human tumor cell
line expressing tumors in nude mice [3], and on mouse
mesothelin in nude mice [26] where mesothelin overexpres-
sion correlated with increased tumor growth. In our mouse
model, the immune system is intact, and since both B and
T lymphocyte responses to mesothelin have been shown
to have some protective efficacy [3, 13, 16, 17, 28, 29],
these data suggest there may be some immune inter-
action in vivo that contributes to the control of tumor
growth.
Analysis of tumor sections however did not show an
increase in leukocytic infiltration or CD8+ cells in
mesothelin over-expressing tumors (Fig. 10), but did
show a clear increase in epithelial to mesenchymal tran-
sition (EMT, Fig. 9). EMT is a complex process con-
trolled by the interplay between tumor cells and the
microenvironment resulting in a change in tumor
phenotype, gene expression, cytokine production, and
resistance to apoptosis and immune mediated effects
[30–32]. Typically EMT is thought to be associated with
an increase in metastasis, but we did not detect any in-
crease in metastasis in these mice. EMT has also been
reported to cause a decrease in tumor cell proliferation
[33], perhaps affecting the rate of tumor formation in
our mesothelin overexpressing tumors. A myriad of cy-
tokines, chemokines, stromal, and innate and adaptive
immune cells interact to create the tumor microenviron-
ment in vivo: how mesothelin affects these complex inter-
actions and tumor growth requires further study. Our
research underscores the importance of evaluating tumor
formation and growth in immunocompetent mouse
models where all components of the natural microenvir-
onment can be assessed.
Conclusions
Mouse mesothelin is similar to human mesothelin in
biochemical characteristics, tumor expression and tissue
distribution. Stable overexpression of mesothelin in a
pancreatic cancer cell line did not increase cell prolifera-
tion or anchorage-independent growth in vitro, suggesting
that mesothelin is not necessarily a tumor progression fac-
tor as previously reported. Overexpression of mesothelin
inhibited tumor formation in vivo, but not growth in vitro.
These data support further research into the effects of
mesothelin expression on tumor development.
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